The second interim analysis of Italian participants enrolled in the real-world, Pan-European, prospective, observational, Phase 4 PEARL study of fremanezumab effectiveness.

ABSTRACT:

Introduction

Migraine burden encompasses social, economic, and functional burden; most notably in individuals with either chronic or high-frequency episodic migraine (CM, HFEM). This second interim sub-analysis of Italian participants with CM and HFEM enrolled in the PEARL study provides updated real-world evidence of fremanezumab use in Italian clinical practice for up to 12 months of treatment.

Methods

In this second interim sub-analysis, data were collected from a sub-population of participants enrolled in PEARL who were treated in Italian headache centers and had completed 12 months of fremanezumab treatment (data cut-off: 15 June 2023). The primary endpoint was the proportion of participants achieving a ≥ 50% reduction in monthly migraine days (MMD) during the 6-month p

SUBMITTER: Vernieri F 

PROVIDER: S-EPMC12678496 | biostudies-literature | 2025 Dec

REPOSITORIES: biostudies-literature